FDA Removes Regulatory Overhang From Inhibikase Therapeutics Parkinson, Atrophy Program
The FDA lifted the full Clinical Hold on Inhibikase Therapeutics Inc’s (NASDAQ:IKT) IkT-148009, the company’s c-Abl inhibitor, in Multiple System…
Short Report Casts Doubt On Piedmont Lithium’s Ghana Deal, Alleges ‘Textbook’ Corruption
In 2021, Piedmont Lithium Inc (NASDAQ: PLL) acquired an equity interest in Atlantic Lithium (OTC: ALLIF), a London-based junior mining company with a deal that would see Piedmont garnering the ability to earn a 50% ow
EXCLUSIVE: Legendary Geologist Stu Averill At PDAC Talks Tower’s Latest Gold Discovery: Is It The Best He’s Ever Seen?
Tower Resources, Ltd (OTC: TWRFF) on March 1, announced it has discovered a second gold zone, which it named Thunder, at the head of its central train, while drilling an inaugural
Roku Ropes In Stitch Fix’s Dan Jedda As New CFO; The Former Amazon Veteran Succeeds Steve Louden
Dan Jedda will join Roku, Inc (NASDAQ:ROKU) as CFO, effective May 1. Jedda will succeed current CFO Steve Louden, who shared…
MyMD Joins LOT Network To Protect Company And Shareholders From Patent Trolls
MyMD Pharmaceuticals, Inc. (NASDAQ: MYMD) has joined LOT Network, the international, non-profit community of companies working together to protect themselves against litigation brought on by patent assertion entities (PAEs, also known as “patent troll
Why Miromatrix Medical Shares Are Falling 40%
Miromatrix Medical Inc (NASDAQ: MIRO) shares are trading lower by 42.41% to $1.42 after the company announced pricing of a $10 million public offering of common stock.
Why Castor Maritime (CTRM) Shares Are Trading Higher
Castor Maritime Inc (NASDAQ: CTRM) shares are trading higher Wednesday morning after the company reported fourth-quarter financial results.
IM Cannabis To Reduce Its Workforce In Israel By Up To 25%
IM Cannabis Corp. (NASDAQ: IMCC) (CSE:IMCC) will be reducing its workforce in Israel by 20%-25% across all functions to strengthen its focus on core activities and drive efficiencies to realize sustainable profitability.
Mesoblast’s Lead Drug Candidate Goes Under FDA Priority Review For Bone Marrow Transplant Complications In Kids
Mesoblast Ltd (NASDAQ:MESO) rallied after the FDA agreed to review the company’s lead drug candidate, remestemcel-L, on a priority basis, more…